

## ABSTRACT SUBMISSION: 789

Status: Unpublished

MY ABSTRACTS	TITLE	CATEGORIES	(HTTPS://EADV.M-ANAGE.COM/MODULES/ABSTRACT/SUBMISSION/BASICS.ASPX) (HTTPS://EADV.M-ANAGE.COM/MODULES/ABSTRACT/SUBMISSION/CATEGORY.ASPX) (HTTPS://EADV.M-ANAGE.COM/MODULES/ABSTRACT/SUBMISSION/AUTHORS.ASPX) (HTTPS://EADV.M-ANAGE.COM/MODULES/ABSTRACT/SUBMISSION/UPLOAD.ASPX) (HTTPS://EADV.M-ANAGE.COM/MODULES/ABSTRACT/SUBMISSION/CONDITIONS.ASPX) (HTTPS://EADV.M-ANAGE.COM/MODULES/ABSTRACT/SUBMISSION/CUSTOMINTEREST.ASPX) (HTTPS://EADV.M-ANAGE.COM/MODULES/ABSTRACT/SUBMISSION/SUMMARY.ASPX)
AUTHORS	UPLOAD		
CONDITIONS	QUESTION		
SUMMARY			

Deadline: 02 March 2021 23:59:00 CET Get the template Your progress

100%

### Todos

- ☒ Enter an abstract title
- ☒ Select a presentation type
- ☒ Select a category
- ☒ Select one author as main author
- ☒ Check the number of authors
- ☒ Check of the uploaded file
- ☒ Use the template
- ☒ Accept the conditions
- ☒ Tell us your custom interest
- ☒ Submit

Red key points mean, that this field needs to be completed.  
Green key points mean, that this field is already completed.

In this window you can see all your abstract data. Please find below also a PDF preview of your abstract.

Please check all your data carefully before finally submitting your abstract. After submission you can not do any changes to the submitted abstract.

You can stop your submission everytime and continue it later - your data will be saved.

When your data is correct and you want to submit your abstract finally, please click on "Publish".

### Summary

Title	Efficacy and Safety of Efgartigimod PH20 SC in Adult Patients with pemphigus vulgaris (PV) and pemphigus foliaceus (PF): ADDRESS, a Global Phase 3 Clinical Trial In Progress
Category	Dermatology and Internal Medicine, including Skin Manifestations of Systemic Diseases
Presentation type	Indifferent
Submitter	Michael Yeakey
Speaker	
Main author	Prof. Pascal Joly <sup>1</sup>



## Authors

Prof. Dr. Enno Schmidt <sup>2</sup>Prof. Zsuzsanna Bata-Csorgo <sup>3</sup>MD Michael Hertl <sup>4</sup>Dr. Russell Hall <sup>5</sup>Dr. Victoria Werth <sup>6</sup>MD, PhD Animesh A. Sinha <sup>7</sup>MD Kristina Seiffert-Sinha <sup>8</sup>Dr. Matthias Goebeler <sup>9</sup>Dr. Johanna Stoevesandt <sup>9</sup>Dr. Peter Verheesen <sup>10</sup>Dr. Patrick Dupuy <sup>10</sup>Dr. Ivaylo Stoykov <sup>10</sup><sup>1</sup> CHU Rouen; Rouen University Hospital; Department of Dermatology, Rouen, France<sup>2</sup> University of Lübeck; University of Lübeck; Department of Dermatology, Lübeck, Germany<sup>3</sup> University of Szeged; Department of Dermatology and Allergology, Szeged, Hungary<sup>4</sup> Philipps-Universität Marburg; Department of Dermatology and Allergology, Marburg, Germany<sup>5</sup> Duke University School of Medicine; Department of Dermatology, Durham, United States<sup>6</sup> University of Pennsylvania; University of Pennsylvania; Dermatology, Philadelphia, United States<sup>7</sup> Jacobs School of Medicine and Biomedical Sciences, University at Buffalo; Department of Dermatology, Buffalo, United States<sup>8</sup> Jacobs School of Medicine and Biomedical Sciences; Department of Dermatology, Buffalo, United States<sup>9</sup> University Hospital Würzburg; Department of Dermatology, Venereology and Allergology, Würzburg, Germany<sup>10</sup> argenx; Ghent, Belgium

## Interests

## Additional information

## Preview



## Introduction

Efgartigimod is an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor (FcRn), thereby reducing the levels of circulating IgG including pathogenic IgG autoantibody levels. PV and PF belong to a heterogeneous group of autoimmune blistering diseases, and are clinically characterized by mucosal erosions (PV) and cutaneous blisters (PV and PF). In PV, IgG autoantibodies primarily target epidermal desmoglein 3 (Dsg-3) and, in the case of mucocutaneous PV, also Dsg-1, while PF is attributed to the presence of IgG autoantibodies directed against Dsg-1. In an interim analysis of a phase 2 trial in mild-to-moderate PV and PF patients, efgartigimod was found to rapidly decrease the serum levels of anti-Dsg-3 and Dsg-1 IgG. Decreases in these autoantibodies were associated with clinical improvement and reduction in disease activity and progression, as shown by the validated clinical scoring system, the Pemphigus Disease Area Index (PDAI).

## Materials and methods

ADDRESS is a global, multicenter, phase 3, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of efgartigimod in patients with PV or PF. Eligible patients are over 18 years old with moderate to severe PV or PF (PDAI activity score  $\geq 15$ ) and are newly diagnosed or relapsing. A total of 150 patients (126 PV and 24 PF) will be randomized and enter a 30-week treatment period to receive either efgartigimod SC co-formulated with PH20 (recombinant human hyaluronidase PH20, an enzyme used to increase the dispersion and absorption of co-administered substances when administered SC) or placebo/PH20 (randomization 2:1). All patients, regardless of treatment assignment, will concomitantly receive oral prednisone (or equivalent) at a starting dose of 0.5 mg/kg daily. On days 1 and 8, patients will receive placebo/PH20 or efgartigimod PH20 SC at a dose of 2,000 mg followed by weekly SC injections of 1,000 mg until complete remission on minimal therapy (CRmin), defined by absence of new lesions and complete healing of established lesions while the patient is receiving minimal prednisone therapy of  $\leq 10$  mg/day for at least 2 months (8 weeks), is achieved. The primary endpoint is the proportion of PV patients who achieve CRmin within 30 weeks. Key secondary endpoints include the proportion of PV and PF patients who achieve CRmin within 30 weeks, cumulative prednisone dose over the trial in PV patients, time to CR in PV patients, and time to disease control (DC) in PV patients. Safety, tolerability, and quality of life will also be assessed during the study. Trial patients will be eligible for continuation into ADDRESS+, a long-term open-label extension trial.

## Results

ADDRESS recruitment is ongoing with a target of 150 patients with PV or PF across approximately 100 sites in 19 countries.

## Discussion

More details on the trials are available on ClinicalTrials.gov (ADDRESS: NCT04598451; ADDRESS+: NCT04598477).

(<https://eadvdistribute.m-anage.com/from.storage?file=XHMrs655afAGZyJdm4mayQBUvFrqfo29ywAkU2I1FiA%3d>)

Back

Pl



